Grace Therapeutics, Inc. (GRCE)

NCM – Real Time Price. Currency in USD

2.33

-0.02 (-0.85%)

At close: May 12, 2026, 4:00 PM EDT

2.33

0.00 (0.00%)

After-hours: May 12, 2026, 7:58 PM EDT

24.04.2026

Grace Therapeutics Stock Falls As FDA Declines To Approve Brain Hemorrhage Drug

Grace Therapeutics Inc. (NASDAQ:GRCE) shares are down during Friday's premarket session following a regulatory update regarding its New Drug Application (NDA) for GTx-104.

23.04.2026

US FDA declines to approve Grace Therapeutics' drug for a type of stroke

Grace Therapeutics said ‌on Thursday the U.S. ⁠Food and Drug Administration declined to approve its drug ‌for ⁠a rare type of ⁠stroke.

23.04.2026

Grace Therapeutics Provides Regulatory Update on New Drug Application for GTx-104

FDA Issued Complete Response Letter Citing Outstanding Items Related to Chemistry, Manufacturing, and Controls and Non-Clinical Information

14.04.2026

Grace Therapeutics Announces Abstract Highlighting STRIVE-ON Phase 3 Trial Results Accepted for Presentation at AAN 2026

PRINCETON, N.J., April 14, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for intravenous infusion to address significant unmet medical needs in aneurysmal subarachnoid hemorrhage (aSAH) patients, today announced that an abstract highlighting the results from the Company's STRIVE-ON Phase 3 Safety Trial has been accepted for presentation at the upcoming 2026 American Academy of Neurology annual meeting, to be held April 18-22, 2026 in Chicago, IL.

19.03.2026

Grace Therapeutics to Present Data on the Unmet Medical Needs and Potential Benefits of GTx-104 in the Treatment of aSAH at Upcoming Medical Conferences

PRINCETON, N.J., March 19, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for intravenous infusion to address significant unmet medical needs in aneurysmal subarachnoid hemorrhage (aSAH) patients, today announced that abstracts discussing the unmet medical needs and the potential benefits of GTx-104 have been accepted for presentation at two major medical conferences taking place in March 2026.

25.02.2026

Grace Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference

PRINCETON, N.J., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address significant unmet medical needs in aneurysmal subarachnoid hemorrhage (aSAH) patients, today announced that Chief Executive Officer Prashant Kohli will participate and present in TD Cowen's 46th Annual Health Care Conference, to be held March 2-4, 2026 in Boston, MA.

12.02.2026

Grace Therapeutics Announces Third Quarter 2026 Financial Results, Provides Business Update

FDA Established April 23, 2026 as PDUFA Target Date for Review of Submission Seeking Approval for GTx-104 in the Treatment of Patients with aneurysmal Subarachnoid Hemorrhage (aSAH) Phase 3 STRIVE-ON Safety Trial Data Presented at 2025 Society of Vascular and Interventional Neurology Annual Meeting Company Continues Pre-Commercial Planning in Anticipation of Potential FDA Approval of NDA Submission for GTx-104 for the Treatment of Patients with aSAH PRINCETON, N.J., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address significant unmet medical needs in aSAH patients, today announced the financial results and business highlights for the quarter ended December 31, 2025.

Videos

No Data

There is no data to display

Press releases

23.04.2026

Grace Therapeutics Provides Regulatory Update on New Drug Application for GTx-104

FDA Issued Complete Response Letter Citing Outstanding Items Related to Chemistry, Manufacturing, and Controls and Non-Clinical Information

14.04.2026

Grace Therapeutics Announces Abstract Highlighting STRIVE-ON Phase 3 Trial Results Accepted for Presentation at AAN 2026

25.02.2026

Grace Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference

12.02.2026

Grace Therapeutics, Inc. (GRCE)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Grace Therapeutics, Inc. (GRCE)

Grace Therapeutics Stock Falls As FDA Declines To Approve Brain Hemorrhage Drug

US FDA declines to approve Grace Therapeutics' drug for a type of stroke

Grace Therapeutics Provides Regulatory Update on New Drug Application for GTx-104

Grace Therapeutics Announces Abstract Highlighting STRIVE-ON Phase 3 Trial Results Accepted for Presentation at AAN 2026

Grace Therapeutics to Present Data on the Unmet Medical Needs and Potential Benefits of GTx-104 in the Treatment of aSAH at Upcoming Medical Conferences

Grace Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference

Grace Therapeutics Announces Third Quarter 2026 Financial Results, Provides Business Update

Videos

No Data

Press releases

Grace Therapeutics Provides Regulatory Update on New Drug Application for GTx-104

Grace Therapeutics Announces Abstract Highlighting STRIVE-ON Phase 3 Trial Results Accepted for Presentation at AAN 2026

Grace Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference

Grace Therapeutics Announces Third Quarter 2026 Financial Results, Provides Business Update

Grace Therapeutics Stock Falls As FDA Declines To Approve Brain Hemorrhage Drug

US FDA declines to approve Grace Therapeutics' drug for a type of stroke

Grace Therapeutics Provides Regulatory Update on New Drug Application for GTx-104

Grace Therapeutics Announces Abstract Highlighting STRIVE-ON Phase 3 Trial Results Accepted for Presentation at AAN 2026

Grace Therapeutics to Present Data on the Unmet Medical Needs and Potential Benefits of GTx-104 in the Treatment of aSAH at Upcoming Medical Conferences

Grace Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference

Grace Therapeutics Announces Third Quarter 2026 Financial Results, Provides Business Update

Videos

No Data

Press releases

Grace Therapeutics Provides Regulatory Update on New Drug Application for GTx-104

Grace Therapeutics Announces Abstract Highlighting STRIVE-ON Phase 3 Trial Results Accepted for Presentation at AAN 2026

Grace Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference

Grace Therapeutics Announces Third Quarter 2026 Financial Results, Provides Business Update

Search stocks

Grace Therapeutics, Inc. (GRCE)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Grace Therapeutics, Inc. (GRCE)

Grace Therapeutics Stock Falls As FDA Declines To Approve Brain Hemorrhage Drug

US FDA declines to approve Grace Therapeutics' drug for a type of stroke

Grace Therapeutics Provides Regulatory Update on New Drug Application for GTx-104

Grace Therapeutics Announces Abstract Highlighting STRIVE-ON Phase 3 Trial Results Accepted for Presentation at AAN 2026

Grace Therapeutics to Present Data on the Unmet Medical Needs and Potential Benefits of GTx-104 in the Treatment of aSAH at Upcoming Medical Conferences

Grace Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference

Grace Therapeutics Announces Third Quarter 2026 Financial Results, Provides Business Update

Videos

No Data

Press releases

Grace Therapeutics Provides Regulatory Update on New Drug Application for GTx-104

Grace Therapeutics Announces Abstract Highlighting STRIVE-ON Phase 3 Trial Results Accepted for Presentation at AAN 2026

Grace Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference

Grace Therapeutics Announces Third Quarter 2026 Financial Results, Provides Business Update

Grace Therapeutics Stock Falls As FDA Declines To Approve Brain Hemorrhage Drug

US FDA declines to approve Grace Therapeutics' drug for a type of stroke

Grace Therapeutics Provides Regulatory Update on New Drug Application for GTx-104

Grace Therapeutics Announces Abstract Highlighting STRIVE-ON Phase 3 Trial Results Accepted for Presentation at AAN 2026

Grace Therapeutics to Present Data on the Unmet Medical Needs and Potential Benefits of GTx-104 in the Treatment of aSAH at Upcoming Medical Conferences

Grace Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference

Grace Therapeutics Announces Third Quarter 2026 Financial Results, Provides Business Update

Videos

No Data

Press releases

Grace Therapeutics Provides Regulatory Update on New Drug Application for GTx-104

Grace Therapeutics Announces Abstract Highlighting STRIVE-ON Phase 3 Trial Results Accepted for Presentation at AAN 2026

Grace Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference

Grace Therapeutics Announces Third Quarter 2026 Financial Results, Provides Business Update